Dissolution and physicochemical stability enhancement of artemisinin and mefloquine co-formulation via nano-confinement with mesoporous SBA-15

Page view(s)
20
Checked on Apr 04, 2024
Dissolution and physicochemical stability enhancement of artemisinin and mefloquine co-formulation via nano-confinement with mesoporous SBA-15
Title:
Dissolution and physicochemical stability enhancement of artemisinin and mefloquine co-formulation via nano-confinement with mesoporous SBA-15
Journal Title:
Colloids and Surfaces B: Biointerfaces
Keywords:
Publication Date:
02 May 2017
Citation:
Letchmanan, K.; Shen, S. C.; Ng, W. K.; Tan, R. B. H., Dissolution and physicochemical stability enhancement of artemisinin and mefloquine co-formulation via nano-confinement with mesoporous SBA-15. Colloids and Surfaces B: Biointerfaces 2017, 155, 560-568.
Abstract:
The objective of this study is to enhance the dissolution rate, supersaturation and physicochemical stability of combination of two poorly water-soluble anti-malarial drugs, artemisinin (ART) and mefloquine (MFQ), by encapsulating them inside mesoporous silica (SBA-15) via co-spray drying. Characteristic studies such as powder X-ray diffraction (PXRD), transmission electron microscopy (TEM) and scanning electron microscope (SEM) clearly indicate the amorphization of the crystalline drugs. ART/MQF/SBA-15 formulations show a superior dissolution enhancement with a burst release of more than 95% of drugs within 30 min. In addition, the combination formulation exhibits a stable supersaturation enhancement by 2-fold higher than that of the untreated crystalline counterparts. ART/MQF/SBA-15 samples possess excellent physicochemical stability under 2 different moderate storage conditions for 6 months. The amorphization of ART and MFQ via nano-confinement using mesoporous SBA-15 is a potentially promising approach to enhance the solubility of poorly water-soluble anti-malarial drugs that co-formulated into a single dosage form.
License type:
http://creativecommons.org/licenses/by-nc-nd/4.0/
Funding Info:
Financial support for this study was provided by project grant R-279-000-329592 from GlaxoSmithKline (GSK) and the Science andEngineering Research Council of A*STAR (Agency for Science, Technology and Research), Singapore.
Description:
ISSN:
0927-7765
1873-4367
Files uploaded: